COPENHAGEN (Reuters) – The European Union’s drug regulator said it would assess two new Danish studies that link Novo Nordisk’s popular diabetes drug Ozempic to a rare eye disease.
The studies published earlier this week had found Ozempic significantly increases the risk of type 2 diabetes patients developing NAION (non-arteritic anterior ischemic optic neuropathy), more than doubling the likelihood.
The European Medicines Agency (EMA) said late on Tuesday that the reviewed evidence from other research so far had not been strong enough to suggest a possible link between Ozempic and the eye disease but that the two Danish studies may hold new important information.
(Reporting by Isabelle Yr Carlsson, Editing by Louise Heavens)
